Mexico - Delayed Quote MXN

Johnson & Johnson (JNJ.MX)

2,983.00

+42.34

+(1.44%)

At close: June 13 at 11:11:18 AM CST

Johnson & Johnson (NYSE:JNJ) Unveils Promising CAR T-Cell Therapy for B-Cell Lymphoma

Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1b study results for its CAR T-cell therapy, JNJ-90014496, indicating potential efficacy in treating large B-cell lymphoma. During the same period, the company saw a 7% share price increase. While the broader market remained flat over the last 7 days, Johnson & Johnson's advancements in cancer treatment likely added weight to its positive stock movement. Other positive developments, such as promising results in acute myeloid...

Simply Wall St. 13 hours ago

JNJ
UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times

Johnson & Johnson (NYSE:JNJ) is one of the best stocks for a retirement stock portfolio. On June 12, UBS global equity strategist Andrew Garthwaite’s team pointed to Johnson & Johnson as one of the top cyclical picks, excluding financials, whose performance tends to move with the broader economy. The stock has gained over 9% in […]

Insider Monkey yesterday

JNJ
Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)

When investors think of artificial intelligence (AI), names like Nvidia (NVDA), Palantir (PLTR), and Alphabet (GOOGL) typically come to mind. But AI’s impact extends well beyond the traditional tech sector. A standout example is Intuitive Surgical (ISRG), the clear global leader in robotic surgery, now making significant strides in integrating AI into healthcare. The company’s latest system, the da Vinci 5, incorporates AI capabilities that could unlock a powerful new and recurring revenue strea

TipRanks yesterday

ISRG

JNJ

MDT
Sector Update: Health Care Stocks Softer Friday Afternoon

Health care stocks declined Friday afternoon, with the NYSE Health Care Index shedding 0.3% and the

PREMIUM
MT Newswires yesterday

JNJ

AZN
JPMorgan biotech/pharma analysts hold analyst/industry conference call

US SMid Biotech Analyst Rama and US Major & Specialty Pharmaceuticals Analyst Schott, along with Dr. Charles Ryan, Genitourinary Medical Oncologist at Memorial Sloan Kettering Cancer Center discuss the evolving treatment landscape in prostate cancer (relevant companies PFE ORIC JNJ) on an Analyst/Industry conference call to be held on June 12 at 2 pm. Webcast Link Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Sto

TipRanks yesterday

ORIC

PFE

JNJ
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

Johnson & Johnson (NYSE: JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not been previously treated with CAR T-cell therapy.1 Findings demonstrate the potential of JNJ-4496 in the treatment of patients with R/R LBCL, including

PR Newswire yesterday

JNJ
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?

Boston Scientific's Q1 2025 Endoscopy sales jump 6%, powered by innovation in stents, clips and surgical tools for GI care.

Zacks yesterday

BSX

JNJ

SYK
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

Johnson & Johnson (NYSE: JNJ) today announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine (VEN + AZA) for the treatment of acute myeloid leukemia (AML) harboring KMT2A gene rearrangements (KMT2Ar) or NPM1 gene mutations (NPM1m). The study evaluated patients with newly diagnosed, intensive chemo-ineligible AML and relapsed or refractory AML.1 The results were featured in an

PR Newswire 2 days ago

JNJ
J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial

The antibody improved joint and skin symptoms in active PsA patients.

Clinical Trials Arena 2 days ago

JNJ
Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit

Johnson & Johnson (NYSE:JNJ) is one of the best Dow stocks to invest in. Recently, a federal judge ruled that a Johnson & Johnson subsidiary must pay $442 million in damages after a jury concluded last month that the company had broken antitrust laws by withholding support from hospitals that used reprocessed catheters. U.S. District […]

Insider Monkey 3 days ago

JNJ
Daniel Pinto Joins Johnson & Johnson (NYSE:JNJ) Board Bringing Extensive Financial Expertise

Johnson & Johnson (NYSE:JNJ) recently announced the election of Daniel Pinto, a seasoned executive with extensive experience, to its Board of Directors, potentially reinforcing its strategic oversight. Over the past month, the company's stock price saw a modest increase of 1.45%, in line with broader market trends, amid its significant advancements in clinical studies such as DARZALEX FASPRO®, presented at the ASCO Annual Meeting. While not directly impactful on this movement, these...

Simply Wall St. 3 days ago

JNJ
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: VACCINE ADVISORY COMMITTEE: In an opinion article published by The Wall Street Journal, Robert F. Kennedy Jr. stated, “Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agenci

TipRanks 3 days ago

RHHBF

RHHBY

RHHVF
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 3 days ago

JNJ
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?

JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.

Zacks 3 days ago

JNJ

MRK
The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile, The Boeing and Franklin Financial Services

JNJ, TMUS, BA, and FRAF show strong momentum as earnings growth, market share, and strategic moves fuel investor confidence.

Zacks 3 days ago

JNJ

BA

TMUS
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 3b APEX study showing that TREMFYA® (guselkumab) significantly reduced both signs and symptoms of active psoriatic arthritis (PsA) and inhibited progression of joint structural damage at 24 weeks compared to placebo.1 These data from a late-breaking abstract are among the 30 oral and poster presentations Johnson & Johnson is highlighting at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress.

PR Newswire 3 days ago

JNJ
Why defensive stocks could be your best bet in a wild market

You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. Think defensive stocks are boring? Dryden Pence, Chief Investment Officer at Pence Capital Management, says you're missing the point. On this episode of Trader Talk, host Kenny Polcari sits down with Pence, a military intelligence veteran turned investment expert, to uncover why defensive sectors like consumer staples, utilities, and healthcare can be your strongest allies in volatile markets. Pence explains how understanding investor psychology, economic fundamentals, and consumer necessities can help investors stay steady amid chaos. If market volatility makes you anxious, this episode might just be the reality check you need. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.

Yahoo Finance Video 3 days ago

JNJ

XLU

XLV
Johnson & Johnson MedTech introduces surgical stapler for tissue complexity

The new stapling technology is set for future exclusive use with the OTTAVA robotic surgical system.

Medical Device Network 3 days ago

JNJ
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

NEW BRUNSWICK, N.J., June 10, 2025--Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors.

Business Wire 4 days ago

JNJ
Top Analyst Reports for Johnson & Johnson, T-Mobile US & Boeing

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, T-Mobile US, and The Boeing Company.

Zacks 4 days ago

BA

TMUS

JNJ

Performance Overview

Return	JNJ.MX	S&P 500 (^GSPC)
YTD	-0.72%	+1.62%
1-Year	+11.57%	+10.00%
3-Year	-14.57%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Johnson & Johnson (JNJ.MX)

Johnson & Johnson (NYSE:JNJ) Unveils Promising CAR T-Cell Therapy for B-Cell Lymphoma

UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times

Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)

Sector Update: Health Care Stocks Softer Friday Afternoon

JPMorgan biotech/pharma analysts hold analyst/industry conference call

Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?

New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial

Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit

Daniel Pinto Joins Johnson & Johnson (NYSE:JNJ) Board Bringing Extensive Financial Expertise

Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel

Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term

JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?

The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile, The Boeing and Franklin Financial Services

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

Why defensive stocks could be your best bet in a wild market

Johnson & Johnson MedTech introduces surgical stapler for tissue complexity

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

Top Analyst Reports for Johnson & Johnson, T-Mobile US & Boeing

Performance Overview